Clinical Trial Update: Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Fragmin (dalteparin) in treating acute venous thromboembolism in pediatric cancer patients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• FRAGMIN (DALTEPARIN SODIUM)

Snippet

Sponsor: Pfizer | Conditions: Venous Thromboembolism | Phase 2 | Status: COMPLETED | Results posted: 2019-04-16